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Abstract
Background: Breast cancer is the most common cancer among women, and radiotherapy plays a major role in its treatment.
However, breast cancer radiotherapy can lead to incidental irradiation of the heart, resulting in an increased risk for a variety of
heart diseases arising many years after radiotherapy. Therefore, identifying breast cancer patients at the highest risk for
radiation-induced cardiac complications is crucial for developing strategies for primary and secondary prevention, which may
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contribute to healthy aging. There is still a need for precise knowledge on the relationship between radiation dose to specific
cardiac structures and early subclinical cardiac changes and their occurrence over time that could finally lead to cardiac
complications.
Objective: The MEDIRAD EARLY HEART study aims to identify and validate new cardiac imaging and circulating biomarkers
of radiation-induced cardiovascular changes arising within first 2 years of breast cancer radiotherapy and to develop risk models
integrating these biomarkers combined with precise dose metrics of cardiac structures based on three-dimensional dosimetry.
Methods: The EARLY HEART study is a multicenter, prospective cohort study in which 250 women treated for breast cancer
and followed for 2 years after radiotherapy will be included. Women treated with radiotherapy without chemotherapy for a
unilateral breast cancer and aged 40-75 years meet the inclusion criteria. Baseline and follow-up data include cardiac measurements
based on two-dimensional speckle-tracking echocardiography, computed tomography coronary angiography, cardiac magnetic
resonance imaging, and a wide panel of circulating biomarkers of cardiac injury. The absorbed dose will be evaluated globally
for the heart and different substructures. Furthermore, the dose-response relationship will allow modeling the radiation-induced
occurrence and evolution of subclinical cardiac lesions and biomarkers to develop prediction models.
Results: This study details the protocol of the MEDIRAD EARLY HEART study and presents the main limits and advantages
of this international project. The inclusion of patients began in 2017. Preliminary results are expected to be published in 2019,
and complete analysis should be published in 2021.
Conclusions: The MEDIRAD EARLY HEART study will allow identifying the main cardiac imaging and blood-based
determinants of radiation-induced cardiac injuries to better propose primary and secondary preventive measures in order to
contribute to enhanced patient care and quality of life.
Trial Registration: ClinicalTrials.gov NCT03297346; https://clinicaltrials.gov/ct2/show/NCT03297346 (Archived by WebCite
at http://www.webcitation.org/72KS7MIUU)
Registered Report Identifier: RR1-10.2196/9906
(JMIR Res Protoc 2018;7(10):e178)   doi:10.2196/resprot.9906
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Introduction
Cancer is a major burden on society, which is expected to
increase worldwide due to the growth and aging of the
population. Furthermore, breast cancer (BC) is the most
commonly diagnosed cancer among women. In 2016, BC
accounted for 29% of the total new cancer cases and 14% of
the total cancer-related deaths among women worldwide [1].
While its incidence has been increasing in the past decade, the
prognosis has markedly improved over the last decades with
enhanced screening and medical support for these patients,
resulting in longer life expectancy and 5-year relative survival
rate > 60%-95% according to the age class in most Western
countries [2]. This is due to improved detection programs and
treatment modalities, including improved radiotherapy (RT)
techniques. In the past few decades, RT has been increasingly
used for the treatment of BC. Research has shown that RT
presents a benefit in terms of reducing local recurrence and
deaths resulting from BC [3]. Due to this increased survival
rate, the interest in potential adverse effects and long-term
consequences related to RT has spiked.
RT plays a major role in the treatment of BC, as >60% of all
BC patients are irradiated as part of their curative treatment,
and it improves outcome in terms of reducing the local
recurrence and deaths resulting from BC [4]. However, BC RT
can lead to incidental irradiation of the heart due to its presence
within the irradiation field, resulting in an increased risk for a
variety of heart diseases arising many years after RT [5], such
as ischemic heart disease, congestive heart failure, arrhythmias,
conduction defects, valvular disease, or pericarditis, with relative
risks within the range of 1.2-3.5 on comparing patients with
left-sided BC (corresponding to patients with higher exposure
to the heart) to patients with right-sided BC [6-8]. In parallel
with the increase in the incidence of BC, the prevalence of BC
survivors at risk for cardiac complications will, thus, gradually
increase [3,4,6-8]. Technological developments in RT over the
last decades, such as intensity-modulated radiotherapy or
volumetric modulated arc therapy and deep inspiration
breath-hold, have allowed for a marked reduction of cardiac
doses, in particular for patients with left-sided BC; the mean
heart dose has decreased from >5 Gy in the 1950s to <3 Gy in
the last decade [9]. It has been shown that the use of these
techniques in BC patients is of concern to the radiation
oncologists and is widely implemented [10,11]. However,
cardiac damage has been shown to be correlated with the mean
heart dose, with a 7.4% increase in the rate of acute coronary
events per 1 Gy (95% CI 2.9-14.5; P<.001), with no minimum
threshold for risk [8]. The risk for acute coronary events within
first 9 years of RT has recently been confirmed by an additional
publication [12], showing marked relationship between cardiac
radiation dose and acute coronary event incidence. Therefore,
as there appears to be no threshold dose below which cardiac
complications do not appear, radiation-induced cardiac diseases
remain potential, severe, late complications of BC RT.
Moreover, dose distributions in the heart are extremely
heterogeneous, and some cardiac substructures such as the apex
and the apical-anterior segment can still receive higher doses.
Therefore, there is still an urgent need for preventive measures.
Long before the onset of clinically significant late cardiac
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complications, subclinical cardiac changes may occur over
weeks, months, or years after RT that can be detected using
anatomical and functional cardiac imaging or circulating
biomarkers [13].
In the context of BC RT-induced functional cardiac changes, a
recent advanced echocardiographic technique (automated
two-dimensional speckle-tracking echocardiography, ECHO-ST,
or cardiac strain] has been used for detecting and quantifying
subtle (subclinical) disturbances in left ventricular strain and
function. A Belgian team first showed that global longitudinal
strain and strain rate were substantially decreased (mean 5%)
during the first year following breast RT [14]. This result was
confirmed by other studies in patients with left-sided BC whose
global longitudinal strain and apical strain were diminished. In
addition, the basal regions showed a compensatory increase in
function, although not sufficient to compensate for the global
functional loss resulting in a decrease in the global longitudinal
strain [14-18]. Moreover, among patients with right-sided BC
RT, a deterioration in basal anterior strain segments after RT
was observed, whereas the global function remained unaffected
[19].
Cardiac computed tomography (CT) without contrast and CT
coronary angiography (CTCA) allows the determination of the
coronary artery calcium (CAC) score and detection of plaques
and stenosis along the coronary arteries. The presence and
diffusion of calcium, plaque, and stenosis expose patients to a
higher risk for coronary artery disease (CAD). Based on an
analysis of 15 segments of coronary arteries per patient with
acute chest pain, an increase in calcified and noncalcified
plaques of around 15% was observed during a 2-year follow-up
[20]. While this study did not consider radiation exposure of
the heart, it does illustrate that the CTCA could be used for
monitoring short-term coronary changes and has the potential
to detect the onset or progression of early coronary changes due
to irradiation among women treated with BC RT. To date, three
studies have measured the amount of CAC in the years following
RT treatment for BC. In two studies, no elevated CAC scores
in BC patients were found 5-15.7 years after RT treatment,
whereas one study did find an increase in the CAC score
depending on the radiation dose to the heart [21-23]. Among
the studies that did not find a CAC score increase, one did not
include baseline CAC scores and the other only included a
relatively small number of patients, making it difficult to draw
definitive conclusions from these two studies. In young
Hodgkin’s lymphoma survivors (all aged <55 years), elevated
CAC scores have been found 5-35 years after RT [24-26]. A
study concerning the general population investigated CAC
scores at baseline and after 10 years of follow-up [27]; the
results showed that the diagnosis of cancer and its treatments
were markedly associated with an increase in CAC scores even
after accounting for cardiac risk factors. The results of these
studies suggest that RT is associated with increased CAC scores
in the long term and, therefore, support the hypothesis that
accelerated atherosclerosis is one of the mechanisms
contributing to an increase in RT-induced cardiac events after
cardiac irradiation.
Cardiac magnetic resonance imaging (MRI), which is considered
as the gold standard to characterize myocardial tissue and
measure ventricular volumes and function, was used to show
that right ventricular systolic function was decreased in a BC
cohort at 24 months after RT [16]. Furthermore, a decline in
temporary ejection fraction was observed on MRI (in patients
treated with three-dimensional [3D] conformal radiotherapy
and not in patients treated with intensity-modulated
radiotherapy) at 6 months, which resolved at 24 months. Left
and right ventricular systolic functions determined using MRI
were reduced at 24 months (but still within the normal range)
for the whole cohort. Furthermore, using T1 mapping, a
promising technique to quantify morphologic tissue injuries, it
was shown in cancer survivors (including BC patients) that
interstitial or diffuse myocardial fibrosis was elevated 3 years
after anthracycline-based chemotherapy independent of the
underlying cancer or comorbidities, suggesting that imaging
biomarkers of interstitial fibrosis are related to prior receipt of
potentially cardiotoxic cancer treatment [28], which may also
include ionizing radiation.
A major challenge is the identification of reliable circulating
biomarkers that could help diagnose and predict cardiotoxicity.
Many classical biomarkers (eg, C-reactive protein, N-terminal
pro-B-type natriuretic peptide, and troponin) have been shown
to be potential biomarkers for cardiac damage after RT [29]. In
addition, circulating inflammatory cytokines indicated tissue
inflammation [30]. Radiation injury to the myocardium is
primarily caused by damage to the microvasculature, leading
to inflammatory and thrombotic changes, capillary loss, focal
ischemia, and interstitial fibrosis [31,32]; these pathological
changes can cause congestive heart failure.
One relatively recent advancement in this area is the discovery
of circulating extracellular vesicles (EVs), including
microparticles and exosomes, and their emergence as mediators
of a new important mechanism of cell-to-cell communication
[33]. The role of EVs in mediating vascular dysfunction suggests
that they may represent novel pathways in short- or
long-distance paracrine intercellular signaling in the vascular
environment. High levels of circulating EVs (involving
microparticles) found in many cardiovascular diseases
demonstrate the importance of platelet, monocyte, and
endothelial activation and could condition remote sustainability
illnesses [34].
Exosomes carry a composite cargo of cardiac microRNAs
(miRNAs). MiRNAs are posttranscriptional inhibitory regulators
of gene expression that are emerging as important mediators of
intercellular communication, being involved in the transmission
of biological signals between cells. To date, several miRNAs
have been identified as having a primary impact on many
biological processes that are of direct relevance to cardiovascular
complications. The exosomal trafficking of miRNAs from the
heart is largely unexplored. Interventional cardiologists have
already provided evidence that cardiac-expressed miRNAs
(miR-1, miR-133a, miR-133b, miR-208a, miR-208b, and
miR-499) increase in the blood acutely following a myocardial
infarction, and some of these studies have additionally
scrutinized the diagnostic potential of miRNAs by comparing
them with cardiac troponin [35,36]. In a clinical study, it has
been demonstrated that the plasma concentration of EVs and
their cargo of cardiac miRNAs increased in patients undergoing
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coronary artery bypass graft and were positively correlated with
cardiac troponin [36]. Another hypothesis that remains to be
explored is that the irradiation may be responsible for an increase
in the number of circulating levels of EVs associated with certain
miRNAs expressed by the cells of the heart tissue. Finally,
studies have examined the global DNA methylation and risk
for cardiovascular disease. The methylation of Bcl-2/adenovirus
E1B 19kD-interacting protein 3, SuperOxyde Dismutase,
Glutathione S-transferase P, Apolipoprotein E, B-cell lymphoma
2, BCL-2-associated X protein, and tissue inhibitor of
metalloproteinases-3 promoters has been associated with the
presence of CAD, which is the most prevalent cardiovascular
disease following the exposure to radiation and may be useful
for diagnostic and monitoring purposes [37].
These previous studies have shown that early subclinical cardiac
changes can occur in BC patients after RT. Additionally,
classical cardiac biomarkers have been shown to be potential
candidates to monitor cardiac damage after RT. Identifying the
main cardiac imaging and blood-based determinants of
radiation-induced cardiac injuries is crucial for developing
strategies for primary and secondary prevention. Primary
prevention includes radiation dose optimization to the most
critical structures of the heart. Secondary prevention requires
identification of patients at risk as early as possible before and
after RT. So far, little has been done regarding the relationship
between dose distribution to different anatomical cardiac
structures during RT and early cardiovascular changes that may
lead to cardiac complications. Mathematical models have been
developed in recent years with the aim of using dosimetric data
to estimate a complication probability—the Normal Tissue
Complication Probability (NTCP) models. Research on
parameters to optimize the NTCP models (physical imaging,
dosimetry, and clinical) is a major challenge to improve
knowledge on the relationship between a received dose and
toxicity to healthy tissue [38,39]. Moreover, the enrichment of
these models with biological data is fundamental to improve
risk prediction. Primary and secondary prevention measures
require precise knowledge of the relationship between the dose
to specific cardiac structures and the occurrence of early
subclinical cardiac changes over time. To date, little has been
done on elucidating the specific relationships between doses to
cardiac structures and subsequent early cardiac toxicity, and
NTCP models have been poorly exploited [40]. However, a
prerequisite for further sparing of tissue subregions, as well as
the analysis of NTCP properties, requires prospective
identification of these structures, and their dose-volume
properties must be taken into account in prospective treatment
planning [41].
In this context, in the frame of the European MEDIRAD project
[42], the EARLY HEART study was launched in July 2017
with the aims of identifying and validating the most important
cardiac imaging biomarkers (based on ECHO-ST, CTCA, and
MRI) and circulating biomarkers of radiation-induced
cardiovascular changes arising within first 2 years of BC RT
and of developing risk prediction models, such as NTCP models,
integrating these biomarkers combined with precise dose metrics
of cardiac structures based on 3D-dosimetry.
Methods
Study Design
MEDIRAD EARLY HEART (NCT03297346) is a multicenter,
prospective cohort study that will include female patients with
left- and right-sided BC treated with postoperative RT without
chemotherapy after primary breast-conserving surgery. The
patients will be followed for 2 years after RT, based on cardiac
imaging and circulating biomarkers further detailed below. Five
investigating centers are involved in the study: Clinique Pasteur
(Toulouse, France) for the Institute of Radiation Protection and
Nuclear Safety (Fontenay-aux-Roses, France), the University
Medical Center Groningen (UMCG; Groningen, the
Netherlands), die Klinikum rechts der Isar der Technischen
Universität München (TUM MED; Munich, Germany), Institut
Català d’Oncologia (Girona, Spain), and Centro Cardiovascular
da Universidade de Lisboa (Lisbon, Portugal). Furthermore,
Paris Descartes University (Paris, France) is involved in the
study as core lab for the centralized analysis of cardiac CT and
cardiac MRI. Data collection is expected to be performed until
autumn 2020.
Ethical Considerations
This study will be conducted in accordance with the Declaration
of Helsinki (amended at the 64th World Medical Association
General Assembly, Fortaleza, Brazil, October 2013) and in
accordance with the principles of “Good Clinical Practice” and
the Medical Research Involving Human Subjects Act (WMO).
The 5 investigating centers have received approvals from their
local ethical committees (France: Comité de Protection de
Personnes Sud-Ouest IV, ID: CPP2015/66/2015-A00990-69–R1,
and Agence Nationale de Sécurité des Médicaments, ID:
150873B-12; the Netherlands: Medisch Ethische
Toetsingscommissie van het Universitair Medisch Centrum
Groningen [METc UMCG], ID: METc 2017/379,
NL62360.042.17; Germany: Ethikkomission der Technischen
Universität München, ID: 235/17 S; Spain: Comitè d’Etica
d’Investigatio CEAi GIRONA, ID: EARLY HEART v1.1
05/07/2017 i FIP v1.3; Portugal: Comissao de Ética do Centro
Hospitalar Lisboa Norte e do Centro Académico de Medicina
de Lisboa [CHLN e CAML], ID: 257/2017).
Study Population, Site Participation, and Recruitment
In this study, we plan to include 250 female patients with
unilateral BC treated at the 5 participating centers with
postoperative modern photon-based planning CT after
breast-conserving surgery, without chemotherapy, who are aged
40-75 years at the time of RT. The determination of the size of
the study population is based on power calculation detailed later.
Textbox 1 details the additional inclusion and exclusion criteria
as well as early dismissal (after inclusion) criteria. Each patient
is included at the baseline before RT and followed for 2 years
after RT. Informed consent of each patient was collected before
inclusion.
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Textbox 1. Inclusion, exclusion, and early dismissal criteria in the EARLY HEART study.
Inclusion criteria
• Female unilateral breast cancer patients
• Treated with primary breast-conserving surgery for stage I-III invasive adenocarcinoma of the breast or ductal carcinoma in situ
• Age 40-75 years at the time of starting radiotherapy
• World Health Organization performance status 0-1
• Planned for radiotherapy alone to the breast with or without the lymph node areas
• Radiotherapy based on planning-computed tomography using either three-dimensional conformal radiotherapy, intensity-modulated radiotherapy,
or volumetric modulated arc therapy/RapidArc
• Written informed consent
Exclusion criteria
• Male breast cancer patients
• Neoadjuvant or adjuvant chemotherapy
• M1 disease (metastatic breast cancer)
• Medical history of coronary artery disease and myocardial infarction and atrial fibrillation
• Previous thoracic or mediastinal radiation
• Contraindications to injection of iodinated contrast such as allergy or renal failure
• Pregnancy or lactation
Dismissal criteria
• Atrial fibrillation detected on electrocardiogram before radiotherapy
• Abnormal echocardiography before radiotherapy defined as either left ventricular ejection fraction <50% or longitudinal strain ≤−16% or
longitudinal strain rate <−1% or abnormal wall motion
• Computed tomography coronary angiography results before radiotherapy requiring revascularization
• Presence of myocardial infarction based on magnetic resonance imaging before radiotherapy
Conduct of the Study
Before Inclusion
At each center, radiation oncologists enable first contact with
women diagnosed with BC. During the first visit with the
radiation oncologist, he or she presents the study and its
implications to female patients for whom RT is planned. The
radiation oncologist ensures that women meet the inclusion
criteria in the study and study information leaflet detailing the
protocol is given with a consent form.
Before Start of Radiotherapy
About 1-2 weeks before the start of RT, women agreeing to
participate in the study hand their signed written informed
consent form and are then considered as included. Once
included, the women’s follow-up protocol is implemented.
Before the start of RT, several interventions are performed.
• An electrocardiogram to detect any arrhythmia, followed
by an automated ECHO-ST, which is the most commonly
used modality to evaluate myocardial dysfunction and a
new technique for assessing myocardial deformation.
• CTCA using both low-dose, nonenhanced and enhanced
CT scans to evaluate coronary artery lesions by assessing
morphological information, including plaques and stenosis
of the arteries, and determination of the CAC score.
• MRI to measure the ventricular function and size and wall
thickness of the two heart chambers; tissue characterization
by delayed enhancement; and pre- or postcontrast T1
mapping and precontrast T2 mapping of the left ventricle.
• Blood sampling (BLOOD) will be performed to allow
analyses of circulating biomarkers based on a panel of
circulating classical and novel blood-based biomarkers
(further details below).
Furthermore, toxicity is assessed according to the Common
Terminology Criteria for Adverse Events (version 4.03), which
is widely accepted throughout the oncology community as the
standard classification and severity grading scale for adverse
events in cancer therapy clinical trials and other oncology
settings.
Subsequent Follow-Up
During subsequent follow-up, imaging and circulating
biomarkers are collected at specific time points after RT up to
24 months: (1) at the end of RT: BLOOD; (2) 6 months after
RT: ECHO-ST, MRI, and BLOOD; (3) 2 years after RT:
electrocardiogram and ECHO-ST, CTCA, MRI, and BLOOD.
Figure 1 describes the different steps of the EARLY HEART
study protocol.
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Figure 1. Main steps of the EARLY HEART study protocol. RT: radiotherapy; BC: breast cancer; BLOOD: blood sample for circulating biomarkers;
ECHO-ST: two-dimensional speckle-tracking echocardiography; CTCA: computed tomography coronary angiography; MRI: magnetic resonance
imaging.
Data Collection
A precise description of the cancer and information about main
risk factors of a cardiac event (eg, age, body mass index [BMI],
smoking status, blood pressure, hypertension, diabetes,
hypercholesterolemia, etc) are collected at inclusion. In addition,
we collect information on the use of hormonotherapy, such as
antiaromatase, as it may lead to an increased cardiovascular risk
[43,44]. Cardiac imaging (ECHO-ST, CT, and MRI) and
circulating biomarkers measurements are detailed in Textbox
2 and Figures 1 and 2. Strain measurements will be based on
automated ECHO-ST, which partly depends on the type of
device (eg, GE, Philips, and Siemens). Not all the centers use
the same device, but each patient from each center will be
followed using the same device; this will allow comparing the
evolution of strain measurements from baseline to the end of
follow-up as a relative value, without been biased by the type
of device [45].
Dosimetry
For cardiac dosimetry, automated segmentation of all cardiac
structures (including coronary arteries) is performed to ensure
the uniformity of the segmentation procedure across centers.
This multiatlas automatic segmentation tool of the heart,
developed by UMCG, is based on the atlas by Feng et al [48]
(Mirada RTx [version 1.6]; Mirada Medical, Oxford, United
Kingdom) [49]. This automatic segmentation allows reducing
the interobserver variability in contouring organs at risk. With
delineated volumes, it is possible to calculate the exact planned
radiation dose for the different volumes of the heart. Using the
individual doses of patients, the dose-effect relationship can be
calculated independently of RT technique or treatment volume.
For the cardiac structures such as the whole heart, left atrium,
right atrium, left ventricle, right ventricle, strain segments of
the left ventricle, and coronary arteries, a minimum dose (Dmin)
is obtained, as well as a maximum dose (Dmax), a mean dose
(Dmean), volumes of the structure receiving at least 1, 2, up to
the total dose of Gy (V1, V2,...until the Vtotal dose). The same is
obtained for the D1, D2, and so on, up to D100 (the dose to 1%,
2%, up to the total of 100% of the volume).
Study Endpoints
Primary Endpoint
The primary endpoint is a mean decrease in the global
longitudinal strain or global longitudinal strain rate, determined
using cardiac ECHO-ST, of at least 2.5% between the baseline
and 24 months after RT [50,51].
Secondary Endpoints
Secondary endpoints are defined as follows:
• Changes in myocardial function compared with baseline
assessed using echocardiography 6-24 months after RT.
• Anatomical changes in coronary artery atherosclerosis
compared with baseline (number of coronary segments
containing any plaque or stenosis and calcium score) on
CTCA 24 months after RT. The endpoint is defined as
≥15% changes.
• Myocardial changes (morphology, function, tissue
characterization by the delayed enhancement, and pre- or
postcontrast T1 mapping) compared with baseline on MRI
6-24 months after RT. The endpoint is an increase in the
mean precontrast T1 mapping value of, at least, 7%.
• Temporal changes in circulating biomarkers at the end of
RT and 6-24 months after RT compared with baseline. The
endpoint is a statistically significant increase or decrease
in each biomarker between time points.
Statistical Analysis
Sample Size Calculation
The MEDIRAD EARLY HEART study includes 250 women.
With 250 patients, this study will have a statistical power of
80% to detect a minimum decrease of 2.5% in global
longitudinal strain between baseline measurement and 24 months
after RT measurement [14]. The baseline value was derived
from the literature: mean global longitudinal strain before RT
= −16.5% (SD 2.1%) [52]. In addition, an alpha level of 5%
was considered, based on paired tests for comparison with the
baseline reference value. Furthermore, the final size was slightly
increased to consider the possible loss to follow-up due to death
or other reason.
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Textbox 2. Main cardiac imaging and circulating biomarkers in the EARLY HEART study.
Two-dimensional speckle-tracking echocardiography
• Global and segmental longitudinal strain and strain rate (more details on the definition of segments in Figure 2 [46])
• Global and segmental radial strain and strain rate
• Left ventricular ejection fraction using Simpson’s biplane method
• E/A wave ratio: ratio of peak velocity blood flow from gravity in early diastole (the E wave) to peak velocity flow in late diastole caused by atrial
contraction (the A wave)
• E/Ea wave ratio: ratio of peak velocity blood flow from gravity in early diastole (the E wave) to Early diastolic velocity of lateral mitral annulus
(e’ lateral)
• Tricuspid annular plane systolic excursion
• Heart rate
• Cardiac output measured by multiplying heart rate by the stroke volume
Computed tomography coronary angiography
• Coronary artery calcium score, based on Agatston, volume, and mass; overall and per artery (left main coronary artery, left anterior descending
artery, left circumflex artery, and right coronary artery)
• Presence and type of plaque (noncalcified, partly calcified, and calcified); overall and per segment or artery (more details in Figure 3 [47])
• Presence and severity of luminal narrowing based on plaque; overall and per segment or artery
Magnetic resonance imaging
• Cardiac morphology: right ventricular end-diastolic and end-systolic volumes, left ventricular end-diastolic and end-systolic volumes, left
ventricular mass, etc
• Cardiac function: left ventricular ejection fraction, right ventricular ejection fraction
• Presence and extent of myocardial infarction based on delayed enhancement
• Tissue characterization based on pre- or postcontrast T1 mapping
• Presence of myocardial edema based on T2 mapping
Circulating biomarkers
• Classical markers:
• Markers of cardiac injury: C-reactive protein, Troponin I, Troponin T, B-type natriuretic peptide (BNP), N-terminal-proBNP,
beta2-microglobulin, Galectin 3
• New biomarkers:
• Extracellular vesicles: microparticles: CD14 (monocytes), CD31 (endothelial), CD41 (platelets), CD3 (lymphocytes), CD235a (erythrocytes);
exosomes
• MicroRNAs (miRNAs): cardiac miRNAs (miR-1, miR-24, miR-133a/b, miR-208a/b, miR-210); noncardiovascular miRNAs (miR-122)
• Circulating DNA methylation
Planned Analysis
Differences in biomarkers between unexposed and paired
exposed groups (eg, right- vs left-sided breast RT) at different
time points will be analyzed to generate preliminary hypotheses
on the effects of RT on the heart. To investigate the time course
of continuous variables extracted from ECHO-ST, CTCA, or
MRI measurements and the relation with radiation dose to a
variety of cardiac structures, mixed regression models will be
used. Confounding variables such as age, blood pressure, BMI,
smoking status, hypertension, hypercholesterolemia, or use of
hormonotherapy will be included in the risk models. Changes
in cardiac biomarkers will be correlated with dose distribution
data. An integrative clinical-biological risk score will be
developed for individual risk prediction and, finally,
multivariable NTCP models will be constructed integrating
these biomarkers combined with dose metrics of cardiac
structures based on 3D-dosimetry.
All statistical analyses will be performed using SAS statistical
software for Windows (SAS Institute, Cary, NC). Furthermore,
linear regression models will be performed using generalized
estimating equations (Proc Genmod) and linear mixed models
(Proc Mixed). An alpha level of .05 will be accepted as
significant.
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Figure 2. Classification of the 17 segments of the left ventricle in bull’s-eye view, echocardiographic parasternal short-axis slices, and apical 4- and
2-chamber views.
Figure 3. The 15 segments of the coronary arteries. LM: left main coronary; LAD: left anterior descending artery; LCX: left circumflex artery; RCA:
right coronary artery.
Results
The inclusion of patients in this European cohort began in 2017.
Preliminary results are expected to be published in 2019, and
complete analysis should be published in 2021.
Discussion
Summary
The MEDIRAD EARLY HEART study is an original
multidisciplinary approach to detect and evaluate early
radiation-induced cardiotoxicity based on a prospective
multicenter cohort study that will finally include 250 patients.
It was designed to combine both cardiac imaging information
regarding potential early myocardial dysfunction, anatomical
coronary changes, and changes in a large panel of circulating
cardiac damage biomarkers occurring within first 2 years of
RT, based on a precise cardiac dosimetry, allowing to analyze
the effect of not only mean heart dose but also doses absorbed
by specific heart structures, which better reflect the heterogeneity
of dose absorbed by the heart. Provided with patients’ own
biological, clinical, and dosimetric parameters, our risk models
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should allow obtaining individualized risk for patients and
enhance knowledge for primary and secondary prevention in
these patients.
Strengths and Limitations
A strength of the MEDIRAD EARLY HEART study is the use
of ECHO-ST, CTCA, and MRI, which is the most complete
approach used for assessing cardiac changes so far. Effects of
specific doses to the whole heart and to specific cardiac
substructures have only been assessed in a few studies [8,53]
that have revealed the importance of better knowledge for
assessing the effects of RT to critical structures of the heart,
including the effect of both radiation dose and volume of the
heart exposed, further illustrated in a previous study that showed
that the use of mean heart dose as a surrogate to the coronary
doses was not reliable [47,53,54]. This heart substructure
dosimetry was retained for the MEDIRAD EARLY HEART
study with an automatic method for the treatment of dosimetry
that should allow us to obtain consistent results. The approach
of simultaneous assessment of multiple biomarkers, including
EVs and cardiac miRNAs, has never been used before and
should help understand some biological mechanisms involved
in the radiation-induced cardiac changes. The study will allow
producing short-term results about subclinical cardiac changes
but will not produce, at this stage, results on long-term
consequences of early cardiovascular changes. The long-term
significance of the observed changes will remain an important
issue, and our results should help focus on “at-risk” patients for
longer follow-ups.
Conclusions
In the context of RT, cardiac risks exist due to the presence of
normal cardiac tissue in the irradiated field; this can,
unfortunately, affect the quality of life of BC survivors, whose
numbers are increasing. As a consequence, there is a need for
further research to improve the early detection of late cardiac
effects in mostly asymptomatic patients and also to improve the
prediction and prevention among these patients [55]. MEDIRAD
EARLY HEART results will allow for the optimization of RT
protocols, leading to personalized treatments with increased
therapeutic efficacy and will, therefore, contribute to improve
the radiation protection of BC patients. Additionally, it should
improve the prediction and prevention of potential lesions to
normal cardiac tissues surrounding tumors and ultimately
enhance patients’ care and quality of life.
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BLOOD: blood sample for circulating biomarkers
CAC: coronary artery calcium
CAD: coronary artery disease
CT: computed tomography
CTCA: computed tomography coronary angiography
ECHO-ST: two-dimensional speckle-tracking echocardiography
EV: extracellular vesicle
miRNAs: microRNAs
MRI: magnetic resonance imaging
NTCP: Normal Tissue Complication Probability
RT: radiotherapy
UMCG: University Medical Center Groningen
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